-
-
EU Confirms Vision Risk Tied to Semaglutide
EMA
EU regulators have confirmed a rare risk of vision loss linked to Novo Nordisk’s semaglutide, used in Wegovy and Ozempic. Drug labels will be updated to reflect the potential for NAION, a serious but very rare eye condition.
-
-
-
EMA Takes Action on Metamizole-Induced Risks
EMA
The EMA has issued new recommendations to mitigate agranulocytosis risks associated with metamizole, urging increased awareness among healthcare providers and patients. Symptoms include fever and sore throat; immediate medical attention is crucial.
-
-
-
EMA's CHMP June 2024 Approvals and Recommendations
EMA
In June 2024, the EMA's CHMP recommended 10 new medicines for approval, including Balversa for urothelial carcinoma and Eurneffy, the first nasal spray for allergic reactions. Notable approvals also include mResvia, an mRNA vaccine for RSV, and treatments for various cancers and rare diseases.
-
-
蓝田县|
玉树县|
东乡族自治县|
门头沟区|
巧家县|
鹤峰县|
霍林郭勒市|
东辽县|
甘洛县|
杨浦区|
永善县|
灌云县|
营山县|
土默特右旗|
德令哈市|
金寨县|
禄丰县|
衡水市|
晴隆县|
山西省|
汕尾市|
吴堡县|
故城县|
常山县|
临沂市|
蒲江县|
革吉县|
定州市|
武义县|
临朐县|
恩平市|
札达县|
曲松县|
嘉黎县|
临夏市|
明星|
南皮县|
武强县|
襄垣县|
饶阳县|
秦皇岛市|